CA
NZ
UK
AU
IND
US
Banzai shares closed Friday, 29 May 2026, at $3.88, up 12.14% on volume of 526,010 shares with relative volume of 0.54x—indicating below-average trading participation. The stock's marketCapitalizationstood at approximately $5.65 million at the close. The advance occurred on a record-setting US market day, with …
Key HighlightsREPL exploded 85.68% on 29 May 2026 to $8.69 (pre-market +60% before the open) after FDA alignment on a path forward for resubmission of the BLA for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma, with the FDA indicating priority review upon receipt.TradingVolumeof …
C4 Therapeutics, Inc. (Nasdaq: CCCC) closed Friday, 29 May 2026 at $4.37, up 19.40% on volume of approximately 5.89 million shares with relative volume of 2.94x. Market cap closed near $483.18 million, with cash and marketable securities of $268.3 million providing a strong funding …
Key HighlightsTSLA fell 1.43% on 29 May 2026 to $435.79 as regulatory data revealed Tesla's robotaxi shortfall: 42 authorized driverless vehicles in Texas versus Waymo's 577, undercutting the central bull thesis.2026 capex guidance above $25 billion (up from prior ~$20B range) is intensifying focus …
Key HighlightsCDZI closed at $4.88, up 11.42% on 29 May 2026 on relativeVolumeof 3.43x (3.06M shares) as a record-setting US market day amplified water-infrastructure sector sentiment and technical buying interest.Catalyst: May 26 funding agreement with US Bureau of Reclamation to support technical and regulatory …
TSS, Inc. (Nasdaq:TSSI) advanced 21.71% on Friday, May 29, 2026, closing at $16.48 on volume of 8.23 million shares, approximately 7.01 times its typical daily average. The move placed TSSI among the session's top gainers on US exchanges, lifting itsMarket Capitalisationto approximately $462.66 million. …
Shares of USA Rare Earth (Nasdaq:USAR) opened pre-market trade on June 1 at approximately $28.19, up around 0.62% from the prior close of $28.01, within a day range of $26.55 to $28.12. The modest advance follows a confluence of announcements including the France expansion …
Agios Pharmaceuticals (Nasdaq: AGIO), a commercial-stage rare disease company, has entered an exclusive global licensing agreement with Oscotec, a clinical-stage immunology and oncology firm headquartered in South Korea, to develop and commercialize cevidoplenib, a next-generation oral spleen tyrosine kinase (SYK) inhibitor. The transaction carries …
Edgewise Therapeutics (Nasdaq: EWTX) has executed a consequential portfolio decision. The company is divesting sevasemten, its late-stage investigational fast skeletal myosin inhibitor for Becker and Duchenne muscular dystrophies, to Servier, an independent French pharmaceutical group. The deal carries $1.55 billion in immediate cash and …
YY Group Holding's stock collapsed 18% on Friday, 29 May 2026, closing at $0.19 per share on approximately 16.62 million shares traded. The decline is particularly noteworthy because it occurred just two days after the company disclosed detailed asset valuations showing net assets per …
Please wait processing your request...